Inflammatix Awarded $1 Million BARDA Contract to Advance TriVerity® as a Tool for Guiding Corticosteroid Therapy in Severe Infection and Sepsis

Project Compass will evaluate TriVerity® as a rapid platform to help predict which patients with severe infection or suspected sepsis may benefit from corticosteroid therapy SUNNYVALE, Calif. — October 14, 2026 — Inflammatix, Inc., a leader in precision diagnostics for acute infection, today announced that it has been awarded a $1 million development contract from […] The post Inflammatix Awarded $1 Million BARDA Contract to Advance TriVerity® as a Tool for Guiding Corticosteroid Therapy in Severe Infection and Sepsis appeared first on Inflammatix .